Analysts Set Qiagen N.V. (NYSE:QGEN) Target Price at $49.40

Shares of Qiagen N.V. (NYSE:QGEN - Get Free Report) have been assigned a consensus recommendation of "Hold" from the ten analysts that are covering the firm, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $49.40.

Several equities research analysts have recently issued reports on QGEN shares. Bank of America increased their price objective on shares of Qiagen from $50.00 to $53.00 and gave the stock a "buy" rating in a research report on Thursday, June 26th. Redburn Atlantic downgraded Qiagen from a "buy" rating to a "neutral" rating in a report on Friday, April 4th. Wall Street Zen upgraded Qiagen from a "buy" rating to a "strong-buy" rating in a research note on Thursday, May 15th. Robert W. Baird increased their target price on Qiagen from $42.00 to $43.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. Finally, Barclays initiated coverage on Qiagen in a research report on Tuesday, June 24th. They set an "overweight" rating and a $55.00 price target on the stock.

Hedge Funds Weigh In On Qiagen

A number of institutional investors have recently made changes to their positions in the business. SVB Wealth LLC acquired a new stake in shares of Qiagen during the first quarter worth approximately $31,000. Brown Brothers Harriman & Co. bought a new stake in shares of Qiagen in the 4th quarter worth about $37,000. EverSource Wealth Advisors LLC raised its stake in shares of Qiagen by 152.5% in the 4th quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company's stock valued at $39,000 after purchasing an additional 526 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in Qiagen by 148.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the company's stock worth $63,000 after purchasing an additional 835 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd bought a new stake in Qiagen in the first quarter valued at about $94,000. 70.00% of the stock is owned by institutional investors and hedge funds.

Qiagen Trading Down 0.6%

Shares of NYSE QGEN traded down $0.30 during trading on Thursday, hitting $48.34. 770,537 shares of the company traded hands, compared to its average volume of 1,200,752. The firm has a market capitalization of $10.75 billion, a P/E ratio of 121.20, a P/E/G ratio of 2.46 and a beta of 0.68. The company has a quick ratio of 2.83, a current ratio of 3.37 and a debt-to-equity ratio of 0.40. The company has a 50-day moving average price of $44.83 and a 200-day moving average price of $42.66. Qiagen has a 1 year low of $37.63 and a 1 year high of $49.30.

Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.05. Qiagen had a return on equity of 14.61% and a net margin of 4.68%. The business had revenue of $483.46 million for the quarter, compared to analyst estimates of $465.66 million. During the same period in the previous year, the company posted $0.44 EPS. The company's revenue was up 5.2% compared to the same quarter last year. On average, equities analysts predict that Qiagen will post 2.26 EPS for the current year.

Qiagen Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Thursday, July 10th. Shareholders of record on Thursday, July 3rd will be paid a dividend of $0.25 per share. The ex-dividend date is Wednesday, July 2nd. This represents a yield of 0.52%. Qiagen's dividend payout ratio (DPR) is presently 62.50%.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.